Enhanced Investments - Financial Portal

DaVita Clinical Research to Present New Findings at American Society of Nephrology Kidney Week 2020

Published: 2020-10-22 13:01:00 ET

Latest research supports improvements in care delivery and patient outcomes

DENVER, Oct. 22, 2020 /PRNewswire/ -- DaVita Clinical Research (DCR) will present 14 research abstracts from company representatives and medical professionals at the American Society of Nephrology (ASN) annual Kidney Week occurring Oct. 22–25, 2020.

Amid the COVID-19 pandemic, ASN Kidney Week 2020 will convene more than 13,000 kidney care professionals from around the world in a virtual format to discuss advancements in the field of nephrology.

"We believe our commitment to pursuing life-enhancing research discoveries is helping accelerate transformation in kidney care," said Dr. Steven Brunelli, vice president and medical director of health economics and outcomes research for DCR. "During these unprecedented times, Kidney Week continues to be a vital convening platform for clinical experts to share meaningful insights and potential real-world solutions that could improve the well-being of medically complex kidney disease patients."

DaVita researchers will report on findings from multiple retrospective studies, with a particular focus on how COVID-19 affects dialysis patients, home dialysis treatments and chronic kidney disease progression.

This year's poster and presentation titles include:

DaVita Clinical Research

Assessment of a Laboratory-Based SARS-CoV-2 Antibody Test Among Hemodialysis Patients: A Quality Improvement Initiative
Management of Secondary Hyperparathyroidism Among Patients Who Transition from Daily At-Home to 3X Weekly Oral Cinaclect Given In-Center
Associations Between Antimicrobial Barrier Cap Use and Outcomes Among Hemodialysis Patients Using a Central Venous Catheter
Urgent Start Peritoneal Dialysis and Outcomes
Longitudinal Assessment of Random Variability in ICH-CAHPS Scores
Use of Predictive Analytics to Inform Integrated Care Programs to Reduce Hospitalizations Among Hemodialysis Patients
Exploration of Racial Disparities in the Kidney Transplant Process Among Dialysis Patients
Use of Incremental Peritoneal Dialysis: Impact on Clinical Outcomes and Quality-of-Life Measures
Patterns of Hospital Admissions Among Patients with Chronic Kidney Disease
Development and Validation of a Predictive Model to Identify Patients with Undiagnosed Chronic Kidney Disease
Inpatient Dialysis Provider Type and Duration of Hospital Admissions of Dialysis Patients
Strategies to Prevent Infection-Related Losses in U.S. Peritoneal Dialysis Programs by More Actionable Predictive Data Reporting
Blood Pressure Telemonitoring in Large U.S. Peritoneal Dialysis Population
Impact of the COVID-19 Pandemic on Virtual Care in Home Dialysis

ASN Kidney Week attendees can view ePosters and pre-recorded presentations from DCR and DaVita Kidney Care clinical leaders at https://www.asn-online.org/kidneyweek/ beginning Oct. 22. DaVita representatives will be available to discuss appropriate opportunities in the Kidney Week digital exhibit hall. Live updates will be shared throughout the meeting on Twitter at @DaVitaDoc and @DaVitaResearch. Attendees, as well as those who cannot participate in the virtual sessions, are encouraged to join or view the conversation by using #KidneyWk.

To learn more about DCR, visit davitaclinicalresearch.com.

About DaVita Clinical Research DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is the research arm of DaVita. DCR innovates through retrospective research aimed at improving clinical outcomes. DCR assists pharmaceutical and medical device companies in the design, recruitment and completion of clinical trials using its renal research site network. To learn more about DCR, visit DaVitaClinicalResearch.com.

About DaVita Inc.DaVita Inc. (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of June 30, 2020, DaVita served 205,300 patients at 2,795 outpatient dialysis centers in the United States and operated 287 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Contact InformationMedia:Halie Peddle(303) 550-6349halie.peddle@davita.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/davita-clinical-research-to-present-new-findings-at-american-society-of-nephrology-kidney-week-2020-301157990.html

SOURCE DaVita Clinical Research

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.